Revvity Pre-Announces Strong Q4 and Full Year 2025 Results, Exceeding EPS Guidance

summarizeSummary

Revvity, Inc. announced preliminary financial results for the fourth quarter and full year 2025, with adjusted earnings per share expected to exceed the high end of previous guidance, signaling strong performance.

check_boxKey Events

• Preliminary Q4 and Full Year 2025 Revenue

  Revvity expects Q4 2025 revenue of approximately $772 million, with reported growth of 6% and organic growth of 4%. Full year 2025 revenue is projected at approximately $2,855 million, with reported growth of 4% and organic growth of 3%.

• Upgraded Full Year Adjusted EPS Guidance

  The company anticipates its full year 2025 adjusted earnings per share to surpass the upper end of its previously provided guidance range of $4.90-$5.00.

• J.P. Morgan Healthcare Conference Presentation

  President and CEO, Dr. Prahlad Singh, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference, with presentation materials furnished as an exhibit.

auto_awesomeAnalysis

Revvity's preliminary financial update indicates stronger-than-expected performance, particularly with the adjusted EPS forecast to exceed prior guidance. This positive pre-announcement suggests healthy operational execution and could lead to a favorable market reaction. Investors will likely focus on the detailed results and any forward-looking commentary during the upcoming earnings call and the J.P. Morgan Healthcare Conference presentation for further insights into the company's trajectory and strategic initiatives.